Changes in Beneficial Ownership · 4
Dianthus Therapeutics, Inc.
DNTHNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
ownership.xml
Filing details
- Report period
- 2026-08-13
- Issuer
- Dianthus Therapeutics, Inc. /DE/
- Issuer CIK
- 0001690585
- Trading symbol
- DNTH
Reporting owner 1
- Name
- Veness Adam M
- Reporting owner CIK
- 0001778623
- Relationship
- Officer
- Officer title
- SVP, General Counsel and Sec.
- Address
- C/O DIANTHUS THERAPEUTICS, INC., 7 TIMES SQUARE, 43RD FLOOR, NEW YORK, NY, 10036
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock | 2026-08-13 | M · Form 4 | 15,000 | A | 18.17 | 15,000 | D |
Table key
- M · Form 4
- Exempt derivative exercise or conversion under Rule 16b-3
- A
- Acquired
- D
- Direct
Derivative transactions
| Security | Conversion / exercise price (USD) | Transaction date | Code | Amount | A / D | Price (USD) | Exercisable | Expires | Underlying security | Underlying shares | Owned after | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy) | 18.17 | 2026-08-13 | M · Form 4 | 15,000 | D | 0 | [F1] | 2033-06-28 | Common Stock | 15,000 | 73,240 | D |
Table key
- M · Form 4
- Exempt derivative exercise or conversion under Rule 16b-3
- D
- Direct
Footnotes
- F1
- The shares of common stock underlying this stock option award vested as to 25% of the shares on June 20, 2024, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date.↩ 1
Signature 1
- Signed
- /s/ Adam Veness
- Date
- 2026-08-14
Company context
Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases. Based in New York City and Waltham, Mass., Dianthus is comprised of an experienced team of biotech and pharma executives who aim to deliver transformative medicines for people living with severe autoimmune and inflammatory diseases.